HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $19.00 price target on the stock.

A number of other analysts have also issued reports on NRXP. D. Boral Capital reiterated a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, March 17th. Ascendiant Capital Markets boosted their price objective on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.08 on Thursday. The business has a fifty day simple moving average of $2.82 and a two-hundred day simple moving average of $2.03. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The company has a market capitalization of $35.19 million, a P/E ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRXP. Townsquare Capital LLC purchased a new position in NRx Pharmaceuticals during the third quarter worth about $25,000. Sassicaia Capital Advisers LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter worth about $33,000. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter worth about $56,000. Millennium Management LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter worth about $61,000. Finally, Anson Funds Management LP purchased a new position in NRx Pharmaceuticals during the third quarter worth about $241,000. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.